Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(4.68) per share which missed the analyst consensus estimate of $(3.18) by 47.17 percent. This is a 148.94 percent decrease over losses of $(1.88) per share from the same period last year. The company reported quarterly sales of $(1.474 million) which missed the analyst consensus estimate of $2.007 million by 173.46 percent. This is a 209.35 percent decrease over sales of $1.348 million the same period last year.